Mesoblast

Company

Investment-firm

Last deal

$40M

Amount

Post-IPO Equity

Stage

26.04.2023

Date

3

all rounds

$452.3M

Total amount

Financing round

General

About Company
Mesoblast is developing and commercializing allogeneic cellular medicines to treat serious and life-threatening inflammatory diseases.

Industry

Sector :

Subsector :

founded date

01.01.2004

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

Mesoblast has a diverse portfolio of cell-based products in advanced clinical stages, targeting areas such as cardiac diseases, orthopedic disorders, oncology, and inflammatory conditions. They have a strong intellectual property portfolio with over 1,000 patents and patent applications, providing global protection. The company's lead product candidates include RYONCIL for acute graft versus host disease, Remestemcel-L for acute respiratory distress syndrome, REVASCOR for chronic heart failure, and MPC-06-ID for chronic low back pain. Mesoblast's proprietary manufacturing processes allow for the production of industrial-scale, off-the-shelf cellular medicines, which are planned to be readily available to patients worldwide.
Contacts
Similar Companies
1000
Axiogenesis

Axiogenesis

Axiogenesis specializes in stem cell-based assays for drug development and in vitro models of healthy and diseased cell types.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Cologne, Germany
Amniotics

Amniotics

Amniotics is a biopharma company specializing in mesenchymal stem cells from amniotic fluid.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Lund, Sweden

total rounds

2

total raised

$2.12M
Apeiron Biologics

Apeiron Biologics

Apeiron Biologics is a biotech company focused on developing novel cancer immunotherapies.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

Vienna, Austria

total rounds

2

total raised

$29.93M
EpiAxis Therapeutics

EpiAxis Therapeutics

EpiAxis Therapeutics is a biotechnology company developing drugs to prevent metastatic disease.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Medical

Location

Canberra ACT 2601, Australia

total rounds

2

Financials

Funding Rounds
8
3

Number of Funding Rounds

$452.3M

Money Raised

Their latest funding was raised on 26.04.2023. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
26.04.2023
$40M
02.03.2021
$110M
13.05.2020
$90M
Investments
1
Date 
name 
Lead 
type 
Raised 
Osiris Therapeutics

Osiris Therapeutics

Osiris Therapeutics develops and sells regenerative medicine products to improve patient health.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Columbia, MD, USA

total rounds

4

total raised

$95M
Co-Investors
Investors
3
3

Number of lead investors

3

Number of investors

Investor 
Lead 
Round 
Partners 

Australian Government for Research & Development

The Australian Government for Research & Development supports research and development initiatives in Australia.

Sector

Media

Subsector

Media Agencies

count Of Investments

4
Novaquest Capital Management

Novaquest Capital Management

NovaQuest Capital Management, LLC manages investments in late-stage clinical and commercialized biopharmaceutical products.

Sector

Open End and Miscellaneous Investment Vehicles

Subsector

Open End and Miscellaneous Investment Vehicles

Keywords

Biotechnology, Financial Services, Health Care

Location

Raleigh, NC, USA

count Of Investments

17

count Of Exists

5

Matthew Bullard

Hercules Capital

Hercules Capital

Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, innovative venture capital-backed companies.

Sector

Investment Banking and Brokerage Services

Subsector

Diversified Financial Services

Keywords

Financial Services, Venture Capital, Finance

Location

Palo Alto, CA, USA

total rounds

2

total raised

$6.5M

count Of Investments

225

count Of Exists

65
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Angioblast Systems acquired by Mesoblast

Angioblast Systems acquired by Mesoblast

acquirer

Mesoblast
Mesoblast

date

12.05.2010

type

Acquisition
Angioblast Systems

Angioblast Systems

Angioblast Systems develops and sells therapeutic products for cardiovascular diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Internet

Location

New York, NY, USA
Exits
1
Osiris Therapeutics

Osiris Therapeutics

Osiris Therapeutics develops and sells regenerative medicine products to improve patient health.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Columbia, MD, USA

total rounds

4

total raised

$95M

People

Founders
2

Michael Schuster

organization founded

1

Michael Schuster

Silviu Itescu
Silviu Itescu

Silviu Itescu

Dr Itescu has served on Mesoblast's Board of Directors since the Company's founding in 2004, was Executive Director from 2007, and became Chief Executive Officer and Managing Director in 2011. Prior to founding Mesoblast in 2004, he established an international reputation as a physician scientist in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. Dr Itescu has been a faculty member of Columbia University in New York, and the University of Melbourne and Monash University in Australia. In 2013, Dr Itescu received the inaugural Key Innovator Award from the Vatican’s Pontifical Council for Culture for his leadership in translational science and clinical medicine in relation to adult stem cell therapy. In 2011, he was named BioSpectrum Asia Person of the Year. He has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of several publicly listed life sciences companies.

current job

Mesoblast
Mesoblast

organization founded

1

Silviu Itescu

Employee Profiles
36

Thomas Cella

Director of national accounts and hospital accounts-cellular therapy

Doreen Morgan

VP Global Regulatory

Eric Koeppel

Regional key account manager

Fred Grossman

Fred Grossman

Chief Medical Officer

Karen Segal

Head of medical affairs

Shawn Tomasello

Board member

Aida Marranzini

Us finance operations lead

Billy Chung

Regulatory publishing associate

Activity

Recent News
17
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range

week